Evecxia’s mission is to help patients suffering from disabling neuropsychiatric conditions for which current therapies are inadequate. Evecxia is the first company dedicated to realizing the therapeutic potential of amplifying serotonin synthesis to treat brain disorders. Serotonin synthesis amplification builds a stronger, more dynamic, more resilient brain endogenous serotonin system. Serotonin synthesis amplification is a distinct pharmacology from targeting serotonin transporters (e.g., serotonin reuptake inhibitors) and receptors (e.g., psilocybin). Evecxia deploys 5-hydroxytryptophan (5-HTP), the natural serotonin precursor, delivered via proprietary drug delivery technologies, to achieve sustained brain serotonin synthesis amplification. Evecxia has two Phase 2 clinical-stage drug candidates in development. EVX-101 is being developed as an adjunctive treatment for depression when first-line serotonin reuptake inhibitor (SSRI/SNRI) antidepressants alone are inadequate. EVX-301 is being developed as a rescue therapy for patients hospitalized for acute suicidal crisis. For additional information about Evecxia, please visit www.evecxia.com.